- call +1-201-465-4211
- email sales@mrinsights.biz
The mAbs, which are produced by genetic engineering, target antigens in cells, tissues, and organs. They are used in clinical applications to treat diseases with excellent efficacy and minimal side effects. Their MOA, absence of generic pathway, and therapeutic applications distinguish them from other targeted therapeutics.
Scope of the Report:
This report focuses on the Cancer Monoclonal Antibodies in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Cancer is one of the leading causes of death globally. There were 10.9 million new cases, in 2002, which increased to 14.1 million, in 2012 (approximately 30% growth in a decade). The WHO expects this number to increase by 70%, over the next two decades. According to the WHO, almost 70% of deaths occur in low and middle-income countries. The increment in data is expected to provide the basis for any national policy on cancer, leading to an increase in the percentage of people choosing cancer treatment. In the healthcare sector, cancer is one of the biggest concerns. Thus, the increased use of monoclonal antibodies for the treatment of cancer is driving this market.
Monoclonal Antibodies having the potential to offer less toxic and efficient therapeutic alternatives to the patients have been emerging in the recent years. Monoclonal Antibodies are used to treat a wide array of diseases related to autoimmune, inflammatory and especially cancer. Monoclonal Antibodies (mAbs) are mono-specific antibodies bodies comprising of identical immune cells that are clones of a single parent cells and are directed to a specific cellular targets. Thus Monoclonal Antibodies are highly customizable due to its specific nature and can play a crucial role in eliminating the cancerous cell while sparing the normal cells during the cancer treatment. The monoclonal antibodies are proved to be more effective than chemotherapies and drugs for cancer treatment.
The worldwide market for Cancer Monoclonal Antibodies is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
F. Hoffmann-La Roche
Amgen
Bristol-Myers Squibb
Takeda Pharmaceuticals
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Murine Antibodies
Chimeric and Humanised Antibodies
Fully Humanized Antibodies
Others
Market Segment by Applications, can be divided into
Liver
Breast
Blood
Brain
Hodgkins and Non-Hodgkins lymphoma
Colorectal
Leukaemia
Others
There are 15 Chapters to deeply display the global Cancer Monoclonal Antibodies market.
Chapter 1, to describe Cancer Monoclonal Antibodies Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Cancer Monoclonal Antibodies, with sales, revenue, and price of Cancer Monoclonal Antibodies, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Cancer Monoclonal Antibodies, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Cancer Monoclonal Antibodies market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Cancer Monoclonal Antibodies sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Cancer Monoclonal Antibodies Introduction
1.2 Market Analysis by Type
1.2.1 Murine Antibodies
1.2.2 Chimeric and Humanised Antibodies
1.2.3 Fully Humanized Antibodies
1.2.4 Others
1.3 Market Analysis by Applications
1.3.1 Liver
1.3.2 Breast
1.3.3 Blood
1.3.4 Brain
1.3.5 Hodgkins and Non-Hodgkins lymphoma
1.3.6 Colorectal
1.3.7 Leukaemia
1.3.8 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 F. Hoffmann-La Roche
2.1.1 Business Overview
2.1.2 Cancer Monoclonal Antibodies Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 F. Hoffmann-La Roche Cancer Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Amgen
2.2.1 Business Overview
2.2.2 Cancer Monoclonal Antibodies Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Amgen Cancer Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Bristol-Myers Squibb
2.3.1 Business Overview
2.3.2 Cancer Monoclonal Antibodies Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Bristol-Myers Squibb Cancer Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Takeda Pharmaceuticals
2.4.1 Business Overview
2.4.2 Cancer Monoclonal Antibodies Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Takeda Pharmaceuticals Cancer Monoclonal Antibodies Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Cancer Monoclonal Antibodies Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Cancer Monoclonal Antibodies Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Cancer Monoclonal Antibodies Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Cancer Monoclonal Antibodies Manufacturer Market Share in 2017
3.3.2 Top 6 Cancer Monoclonal Antibodies Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Cancer Monoclonal Antibodies Market Analysis by Regions
4.1 Global Cancer Monoclonal Antibodies Sales, Revenue and Market Share by Regions
4.1.1 Global Cancer Monoclonal Antibodies Sales and Market Share by Regions (2013-2018)
4.1.2 Global Cancer Monoclonal Antibodies Revenue and Market Share by Regions (2013-2018)
4.2 North America Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
4.3 Europe Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
4.5 South America Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
5 North America Cancer Monoclonal Antibodies by Countries
5.1 North America Cancer Monoclonal Antibodies Sales, Revenue and Market Share by Countries
5.1.1 North America Cancer Monoclonal Antibodies Sales and Market Share by Countries (2013-2018)
5.1.2 North America Cancer Monoclonal Antibodies Revenue and Market Share by Countries (2013-2018)
5.2 United States Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
5.3 Canada Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
5.4 Mexico Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
6 Europe Cancer Monoclonal Antibodies by Countries
6.1 Europe Cancer Monoclonal Antibodies Sales, Revenue and Market Share by Countries
6.1.1 Europe Cancer Monoclonal Antibodies Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Cancer Monoclonal Antibodies Revenue and Market Share by Countries (2013-2018)
6.2 Germany Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
6.3 UK Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
6.4 France Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
6.5 Russia Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
6.6 Italy Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
7 Asia-Pacific Cancer Monoclonal Antibodies by Countries
7.1 Asia-Pacific Cancer Monoclonal Antibodies Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Cancer Monoclonal Antibodies Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Cancer Monoclonal Antibodies Revenue and Market Share by Countries (2013-2018)
7.2 China Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
7.3 Japan Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
7.4 Korea Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
7.5 India Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
8 South America Cancer Monoclonal Antibodies by Countries
8.1 South America Cancer Monoclonal Antibodies Sales, Revenue and Market Share by Countries
8.1.1 South America Cancer Monoclonal Antibodies Sales and Market Share by Countries (2013-2018)
8.1.2 South America Cancer Monoclonal Antibodies Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
8.3 Argentina Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
8.4 Colombia Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
9 Middle East and Africa Cancer Monoclonal Antibodies by Countries
9.1 Middle East and Africa Cancer Monoclonal Antibodies Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Cancer Monoclonal Antibodies Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Cancer Monoclonal Antibodies Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
9.3 UAE Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
9.4 Egypt Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
9.5 Nigeria Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
9.6 South Africa Cancer Monoclonal Antibodies Sales and Growth Rate (2013-2018)
10 Global Cancer Monoclonal Antibodies Market Segment by Type
10.1 Global Cancer Monoclonal Antibodies Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Cancer Monoclonal Antibodies Sales and Market Share by Type (2013-2018)
10.1.2 Global Cancer Monoclonal Antibodies Revenue and Market Share by Type (2013-2018)
10.2 Murine Antibodies Sales Growth and Price
10.2.1 Global Murine Antibodies Sales Growth (2013-2018)
10.2.2 Global Murine Antibodies Price (2013-2018)
10.3 Chimeric and Humanised Antibodies Sales Growth and Price
10.3.1 Global Chimeric and Humanised Antibodies Sales Growth (2013-2018)
10.3.2 Global Chimeric and Humanised Antibodies Price (2013-2018)
10.4 Fully Humanized Antibodies Sales Growth and Price
10.4.1 Global Fully Humanized Antibodies Sales Growth (2013-2018)
10.4.2 Global Fully Humanized Antibodies Price (2013-2018)
10.5 Others Sales Growth and Price
10.5.1 Global Others Sales Growth (2013-2018)
10.5.2 Global Others Price (2013-2018)
11 Global Cancer Monoclonal Antibodies Market Segment by Application
11.1 Global Cancer Monoclonal Antibodies Sales Market Share by Application (2013-2018)
11.2 Liver Sales Growth (2013-2018)
11.3 Breast Sales Growth (2013-2018)
11.4 Blood Sales Growth (2013-2018)
11.5 Brain Sales Growth (2013-2018)
11.6 Hodgkins and Non-Hodgkins lymphoma Sales Growth (2013-2018)
11.7 Colorectal Sales Growth (2013-2018)
11.8 Leukaemia Sales Growth (2013-2018)
11.9 Others Sales Growth (2013-2018)
12 Cancer Monoclonal Antibodies Market Forecast (2018-2023)
12.1 Global Cancer Monoclonal Antibodies Sales, Revenue and Growth Rate (2018-2023)
12.2 Cancer Monoclonal Antibodies Market Forecast by Regions (2018-2023)
12.2.1 North America Cancer Monoclonal Antibodies Market Forecast (2018-2023)
12.2.2 Europe Cancer Monoclonal Antibodies Market Forecast (2018-2023)
12.2.3 Asia-Pacific Cancer Monoclonal Antibodies Market Forecast (2018-2023)
12.2.4 South America Cancer Monoclonal Antibodies Market Forecast (2018-2023)
12.2.5 Middle East and Africa Cancer Monoclonal Antibodies Market Forecast (2018-2023)
12.3 Cancer Monoclonal Antibodies Market Forecast by Type (2018-2023)
12.3.1 Global Cancer Monoclonal Antibodies Sales Forecast by Type (2018-2023)
12.3.2 Global Cancer Monoclonal Antibodies Market Share Forecast by Type (2018-2023)
12.4 Cancer Monoclonal Antibodies Market Forecast by Application (2018-2023)
12.4.1 Global Cancer Monoclonal Antibodies Sales Forecast by Application (2018-2023)
12.4.2 Global Cancer Monoclonal Antibodies Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Cancer Monoclonal Antibodies Picture
Table Product Specifications of Cancer Monoclonal Antibodies
Figure Global Sales Market Share of Cancer Monoclonal Antibodies by
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
